EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 2nd, 2015 • Raptor Pharmaceutical Corp • Pharmaceutical preparations • California
This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of October 13, 2014, by and between David Happel (“Executive”) and Raptor Pharmaceutical Corp. (the “Company”).
RAPTOR PHARMACEUTICAL CORP. Award AgreementEmployment Agreement • March 2nd, 2015 • Raptor Pharmaceutical Corp • Pharmaceutical preparations • Delaware
In consideration of your commencement of employment with the Company and for other good and valuable consideration, effective as of the Grant Date set forth below, you are hereby awarded this stock option (“Option”) (in electronic format) to purchase Shares of Raptor Pharmaceutical Corp. (the “Company”), subject to the terms and conditions set forth in this Stock Option Award Agreement (the “Award Agreement”) and in the Raptor Pharmaceutical Corp. 2014 Employment Commencement Stock Incentive Plan (the “Plan”). A copy of the Plan is attached as Exhibit A, and a prospectus describing the Plan’s material terms is attached as Exhibit B. Terms below that begin with capital letters have the special meaning set forth in the Plan or in this Award Agreement.
FOURTH AMENDMENT to LICENSE AGREEMENT UC CONTROL NUMBER 2008-03-0236, EFFECTIVE OCTOBER 31, 2007 between RAPTOR PHARMACEUTICALS, INC. and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA for: CASE NO. SD2006-092: “Enterically Coated Cysteamine”License Agreement • March 2nd, 2015 • Raptor Pharmaceutical Corp • Pharmaceutical preparations • California
This fourth amendment (“Fourth Amendment”) to the License Agreement, UC Control No. 2008-03-0236, for Case No. SD2006-092 “Enterically Coated Cysteamine” effective October 31, 2007, as amended as of November 11, 2008, amended and restated as of October 30, 2012 and amended as of March 1, 2013 (“Agreement”) is made as of December 16, 2013 (the “4th Amendment Date”) by and between Raptor Pharmaceuticals, Inc. (f/k/a Raptor Therapeutics, Inc.), a Delaware corporation having an address at 5 Hamilton Landing, Suite 160, Novato, CA, 94949 (“LICENSEE”) and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Technology Transfer Office, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UCSD”).
THIRD AMENDMENT to LICENSE AGREEMENT UC CONTROL NUMBER 2008-03-0236, EFFECTIVE OCTOBER 31, 2007 between RAPTOR THERAPEUTICS, INC. and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA for: CASE NO. SD2006-092: “Enterically Coated Cysteamine”License Agreement • March 2nd, 2015 • Raptor Pharmaceutical Corp • Pharmaceutical preparations • California
This third amendment (“Third Amendment”) to the License Agreement, UC Control No. 2008-03-0236, for Case No. SD2006-092 “Enterically Coated Cysteamine” effective October 31, 2007, as amended and restated as of October 30, 2012, (“Agreement”) is made as of 1 March, 2013 (the “Amendment Date”) by and between Raptor Pharmaceuticals, Inc. (f/k/a Raptor Therapeutics, Inc.), a Delaware corporation having an address at 9 Commercial Blvd., Suite 200, Novato, CA, 94949 (“LICENSEE”) and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Technology Transfer Office, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UCSD”).
